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Abstract
Introduction: Estrogen receptor a-positive (ER+) breast cancers adapt to hormone deprivation and acquire
resistance to antiestrogen therapies. Upon acquisition of hormone independence, ER+ breast cancer cells increase
their dependence on the phosphatidylinositol-3 kinase (PI3K)/AKT pathway. We examined the effects of AKT
inhibition and its compensatory upregulation of insulin-like growth factor (IGF)-I/InsR signaling in ER+ breast cancer
cells with acquired resistance to estrogen deprivation.
Methods: Inhibition of AKT using the catalytic inhibitor AZD5363 was examined in four ER+ breast cancer cell lines
resistant to long-term estrogen deprivation (LTED) by western blotting and proliferation assays. Feedback
upregulation and activation of receptor tyrosine kinases (RTKs) was examined by western blotting, real-time qPCR,
ELISAs, membrane localization of AKT PH-GFP by immunofluorescence and phospho-RTK arrays. For studies in vivo,
athymic mice with MCF-7 xenografts were treated with AZD5363 and fulvestrant with either the ATP-competitive
IGF-IR/InsR inhibitor AZD9362 or the fibroblast growth factor receptor (FGFR) inhibitor AZD4547.
Results: Treatment with AZD5363 reduced phosphorylation of the AKT/mTOR substrates PRAS40, GSK3a/b and S6K
while inducing hyperphosphorylation of AKT at T308 and S473. Inhibition of AKT with AZD5363 suppressed growth
of three of four ER+ LTED lines and prevented emergence of hormone-independent MCF-7, ZR75-1 and MDA-361
cells. AZD5363 suppressed growth of MCF-7 xenografts in ovariectomized mice and a patient-derived luminal B
xenograft unresponsive to tamoxifen or fulvestrant. Combined treatment with AZD5363 and fulvestrant suppressed
MCF-7 xenograft growth better than either drug alone. Inhibition of AKT with AZD5363 resulted in upregulation
and activation of RTKs, including IGF-IR and InsR, upregulation of FoxO3a and ERa mRNAs as well as FoxO- and ER-
dependent transcription of IGF-I and IGF-II ligands. Inhibition of IGF-IR/InsR or PI3K abrogated AKT PH-GFP
membrane localization and T308 P-AKT following treatment with AZD5363. Treatment with IGFBP-3 blocked
AZD5363-induced P-IGF-IR/InsR and T308 P-AKT, suggesting that receptor phosphorylation was dependent on
increased autocrine ligands. Finally, treatment with the dual IGF-IR/InsR inhibitor AZD9362 enhanced the anti-tumor
effect of AZD5363 in MCF-7/LTED cells and MCF-7 xenografts in ovariectomized mice devoid of estrogen
supplementation.
Conclusions: These data suggest combinations of AKT and IGF-IR/InsR inhibitors would be an effective treatment
strategy against hormone-independent ER+ breast cancer.
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Introduction
AKT is a serine/threonine kinase downstream of phos-
phatidylinositol-3 kinase (PI3K) that plays a critical role
in cellular survival, proliferation, metabolism and resis-
tance to apoptosis [1]. Upon activation by growth factor
receptor tyrosine kinases (RTKs) and G-protein-coupled
receptors, PI3K phosphorylates phosphatidylinositol
4,5-bisphosphate (PIP2) to produce phosphatidylinositol
3,4,5-trisphosphate (PIP3). PIP3 then recruits pleckstrin
homology (PH) domain-containing proteins such as PDK1,
SGK and AKT to the plasma membrane, where AKT is
phosphorylated at T308 by PDK-1 and, subsequently, at
S473 by TORC2, becoming fully activated [1,2].
The PI3K/AKT signaling pathway is the most frequently
mutated pathway in breast cancer [2-4]. PI3K is activated
via several mechanisms, including gain-of-function muta-
tions in the PI3K catalytic subunit p110a (PIK3CA) and
regulatory subunit p85a (PIK3R1), amplification of wild
type PIK3CA, p110b (PIK3CB) and PDK1, loss/inactiva-
tion of the PIP3 phosphatases PTEN and INPP4B, muta-
tion and/or amplification of AKT1-3 and amplification of
RTKs, such as HER2, IGF-IR, MET, FGFR1 and EGFR
[3,5]. These cumulative data have suggested AKT as a
rational molecular target for breast cancer therapy.
About 80% of breast cancers express estrogen receptor
a (ER) and/or progesterone receptor (PR), biomarkers
indicative of hormone dependence [6]. Therapies against
ER+ breast cancers inhibit ER function either by antago-
nizing ligand binding to ER (tamoxifen), downregulating
ER (fulvestrant) or blocking estrogen biosynthesis (aro-
matase inhibitors (AIs)). However, many tumors exhibit
de novo or acquired resistance to endocrine therapies.
Overexpression of the ErbB2/HER2 protooncogene has
been shown to promote clinical resistance to antiestro-
gen therapy [7,8]. However, <10% of ER+ breast cancers
overexpress HER2, suggesting that, for the majority of
ER+ breast cancers, mechanisms of escape from endo-
crine therapy remain to be discovered.
The PI3K pathway has been causally associated with
resistance to endocrine therapy [9-14]. Upon acquisition
of hormone independence, ER+ breast cancer cells
increase their dependence on PI3K/AKT signaling [9].
Herein we show that inhibition of AKT using the cataly-
tic inhibitor AZD5363, currently in phase I clinical
trials, suppressed hormone-independent ER+ breast can-
cer growth. However, upregulation of IGF-IR/InsR and
their ligands compensated for AKT inhibition and lim-
ited the effect of AZD5363. Addition of an IGF-IR/InsR
tyrosine kinase inhibitor (TKI) enhanced the action of
AZD5363 against MCF-7 xenografts in ovariectomized
mice devoid of estrogen supplementation, suggesting a
novel and testable therapeutic combination for patients
with ER+ breast cancer.
Methods
Cell lines
Cell lines (ATCC, Manassas, VA, USA) were maintained
in improved minimum essential medium (IMEM)/10%
fetal bovine serum (FBS) (Life Technologies, Grand
Island, NY, USA) and authenticated by short tandem
repeat profiling using Sanger sequencing (sequenced in
March 2011). Long-term estrogen deprived (LTED) cells
were generated and maintained in phenol red-free
IMEM with 10% dextran/charcoal-treated FBS (DCC-
FBS) [9].
Immunoblot analysis and RTK arrays
Lysates from cells treated with AZD5363 [15], IGF-I,
IGF-II, IGFBP-3 (R&D Systems, Minneapolis, MN,
USA), AEW541 [16] or BKM120 [17] (Selleck Chemi-
cals, Houston, TX, USA) were subjected to SDS-PAGE,
transferred to nitrocellulose and analyzed by immunoblot
analysis [9] using antibodies against P-AKTS473,
P-AKTT308, AKT, P-PRAS40, P-GSK-3a/b, P-S6S240/244, S6,
P-IGF-IRbY1131/P-InsRbY1146, P-HER3Y1197, P-HER2Y1248,
P-SrcY416, P-FRS2-aY436, EGFR (Cell Signaling, Danvers,
MA, USA), InsRb, IGF-IRb, ERa (F-10), HER3, HER4,
FGFR2 (Santa Cruz Biotechnology, Dallas, TX, USA),
HER2 (NeoMarkers, Fremont, CA, USA), PR (Dako,
Carpinteria, CA, USA), IRS-1 (EMD Millipore, Billerica,
MA, USA), and actin (Sigma-Aldrich, St. Louis, MO, USA).
Densitometric analysis was performed using ImageJ. Phos-
pho-RTK arrays were performed using the Human Phos-
pho-RTK Array Kit according to the manufacturer’s
protocol (R&D Systems).
Cell proliferation
Cells seeded in triplicate in 12-well plates (2.5 × 104
cells/well for MCF-7/LTED and 4 × 104 cells/well for
other lines) were treated in 10% DCC-FBS ± AZD5363,
selumetinib (AZD6244, ARRY-142886) [18] (Selleck
Chemicals), fulvestrant (ICI 182780, R&D Systems), 17b-
estradiol (E2) or AZD9362 (AstraZeneca, Cambridge,
MA, USA). AZD9362 is a reversible, ATP-competitive
small molecule inhibitor of IGF-IR and insulin receptor.
In isolated enzyme assays, it inhibits the IGF-IR enzyme
with an IC50 of 14 nM. In cellular assays, the compound
prevents autophosphorylation of IGF-IR in fibroblasts
from IGF-IR knockout mice stably transfected with
human IGF-IR with an IC50 of 48 nM; it inhibits autop-
hosphorylation of human InsR in CHO-T cells with an
IC50 of 186 nM. AZD9362, dosed at 25 mg/kg qd, also
inhibits phosphorylation of IGF-IR by >50% for at least
six hours and induces >70% inhibition of tumor volume
in NIH3T3 fibroblasts stably transfected with IGF-IR.
Media and inhibitors for proliferation assays were replen-
ished every three days; after five to ten days, adherent
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cells were trypsinized and counted using a Coulter Coun-
ter or fixed/stained with crystal violet [9]. For siRNA
experiments, cells were transfected in 100-mm dishes
using HiPerfect Transfection Reagent according to the
manufacturer’s protocol (Qiagen, Germantown, MD,
USA). The next day, cells were re-seeded in 10% DCC-
FBS for immunoblot analyses as described previously [9]
or cell proliferation assays and counted five to ten
days later. siRNAs targeting IGF-IR, InsR, HER3, or non-
silencing control were obtained from Qiagen.
Real-time qPCR
Cells grown in 10% DCC-FBS ± AZD5363 were har-
vested and their RNA extracted using the RNeasy Mini
Kit (Qiagen). Using the iScript cDNA Synthesis Kit
(Bio-Rad, Hercules, CA, USA), 1 µg of RNA was reverse
transcribed to cDNA and real-time PCR reactions were
conducted in 96-well plates using the iCycler iQ (Bio-
Rad) and primers obtained from SABiosciences (Qia-
gen). For siRNA experiments, cells were transfected
with siRNA targeting forkhead box class O (FoxO3)
(Life Technologies), ER or non-silencing control (Qia-
gen) using Dharmafect 1 according to the manufac-
turer’s protocol (Thermo Fisher Scientific, Pittsburgh,
PA, USA). Two days later cells were treated with 10%
DCC-FBS ± 2 µM AZD5363 for 24 hours followed by
RNA isolation and RT qPCR.
Confocal microscopy
MCF-7/LTED cells plated in 35-mm dishes with No. 1.5
coverglass coated with Poly-d-lysine (MatTek, Ashland,
MA, USA) were transfected with 2.5 µg of an AKT-PH-
GFP plasmid (provided by Dr. Gordon Mills, MD Anderson
Cancer Center, Houston, TX, USA) using Lipofectamine
2000 according to the manufacturer’s protocol (Invitrogen,
Life Technologies, Grand Island, NY, USA). On day four,
cells were treated with 10% DCC-FBS ± AZD5363,
AEW541 or BKM120 for four hours. Cells were viewed on
an LSM 510Meta confocal microscope at 40x magnification
at the Vanderbilt University Cell Imaging Shared Resource.
Mouse xenograft experiments
Animal experiments were approved by the Vanderbilt
Institutional Animal Care and Use Committee. Female
ovariectomized athymic mice were implanted s.c. with a
14-day-release E2 pellet (0.17 mg; Innovative Research
of America, Sarasota, Florida, USA). The next day, 107
MCF-7 cells suspended in IMEM and mixed with matri-
gel (BD Biosciences, San Jose, California, USA) at 1:1
ratio were injected s.c. into the right flank of each
mouse. After >2 weeks, mice bearing tumors ≥150 mm3
were randomized to treatment with vehicle (25% (2-
hydroxypropyl)-b-cyclodextrin), AZD5363 (150 or
100 mg/kg bid p.o.), fulvestrant (5 mg/week i.p.),
AZD9362 (25 mg/kg/day p.o.) or AZD4547 [19]
(12.5 mg/kg/day p.o.). Combining 150 mg/kg/day
AZD5363 with AZD9362 and AZD4547 resulted in exces-
sive toxicity, so a lower dose of AZD5363 (100 mg/kg/day
p.o.) was used in this experiment. Tumor diameters were
measured twice weekly and volume in mm3 calculated as
volume = width2 x length/2. Tumors were harvested one
or four hours after the last dose of AZD5363 or 24 hours
after the last dose of fulvestrant and flash-frozen in liquid
nitrogen or fixed in 10% formalin prior to paraffin-embed-
ding. Frozen tumors were homogenized using the Tissue-
Lyser II (Qiagen). Tumor lysates were prepared, subjected
to SDS-PAGE, transferred to nitrocellulose and analyzed
by immunoblot analysis [9].
Statistics
In cell proliferation assays, significant differences were
determined by one-way analysis of variance (ANOVA)
(one cell line) or two-way ANOVA with Bonferroni
post-hoc tests corrected for multiple comparisons.
Unpaired t-tests were used to determine significant dif-
ferences in crystal violet assays and real-time qPCR
assays. Two-way ANOVA with Bonferroni post-hoc
tests corrected for multiple comparisons was used to
determine significance in real-time qPCR assays com-
paring multiple cell lines. In tumor growth assays, sig-
nificant differences were determined by unpaired t-tests.
Significant differences in immunohistochemistry (IHC)
histoscores were determined by unpaired t-tests. P <
0.05 was considered significant.
[See Additional file 1 for Supplementary materials and
methods.]
Results
Inhibition of AKT suppresses hormone-independent
breast cancer cell growth
We previously established a panel of ER+ breast cancer
cell lines with acquired resistance to LTED [9]. Treatment
with the ATP-competitive AKT inhibitor AZD5363 [15]
reduced phosphorylation of the AKT/TORC1 substrates
PRAS40, GSK-3a/b and S6K while inducing hyperpho-
sphorylation of AKT in S473 and T308 (Figure 1A).
Similar results were seen in MCF-7, ZR75-1 and HCC-
1428 parental cells [see Additional file 2, Figure S1]. Cataly-
tic inhibitors of AKT block the activity of the enzyme but
release compensatory feedback leading to activation of
PI3K and more formation of PIP3 at the membrane. Thus,
these compounds do not prevent the recruitment of AKT,
via its PH domain, to PIP3 at the plasma membrane. Upon
reactivation of PI3K and PIP3 formation, AKT is recruited
to the plasma membrane where PDK1 and TORC2 phos-
phorylate T308 and S473, respectively [20]. As a result,
in cells treated with AZD5363, AKT is (hyper) phosphory-
lated but catalytically inactive (Figure 1A, Figure S1 in
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Additional file 2; ref [15]). Inhibition of AKT with ≤2 µM
AZD5363 suppressed the growth of three of the four
LTED lines (Figure 1B). To determine whether AKT is
required for the emergence of hormone-independence, we
reselected parental cells in estrogen-free medium. Treat-
ment with AZD5363 (0.4 to 2 µM) prevented or delayed the
emergence of hormone-independent MCF-7, ZR75-1 and
MDA-361 cells (Figure 1C; Additional file 2, Figure S2).
Notably, all three of these cell lines contain PI3K pathway
alterations (MCF-7 and MDA-361, PIK3CA mutation;
ZR75-1, PTEN null), whereas the unresponsive HCC-1428
line does not. In comparison, inhibition of MEK1/2 with
selumetinib (AZD6244) [18] induced a more modest inhibi-
tion of colony formation in three of the four cell lines tested
(Figure 1C; Figure S2 in Additional file 2). AZD5363 also
suppressed E2-induced growth in monolayer (data not
shown).
Combined inhibition of AKT and ER suppresses growth
of MCF-7 xenografts
Upon escape from hormone deprivation, some ER+
tumor cells retain estrogen (ligand)-independent ER
function. PI3K/AKT can phosphorylate and activate ER
transcription in the absence of estradiol [12]. Estrogen
deprivation induces synthetic lethality in ER+ breast
cancer cells treated with a PI3K inhibitor or transfected
with p110 siRNA [13], suggesting compensatory cross-
talk between ER and PI3K/AKT signaling. Consistent
Figure 1 Catalytic AKT inhibitor suppresses LTED growth and prevents emergence of hormone-independent breast cancer cells.
A) LTED cells were treated with 10% DCC-FBS ± 0 to 15 µM AZD5363 for 24 hours. Protein lysates were analyzed by immunoblot using the
indicated antibodies. B) LTED cells were treated with 10% DCC-FBS ± 0.4 or 2 µM AZD5363. Media and drugs were replenished every three days.
Cells were counted after five to ten days. Data are presented as percent of control; each bar, mean ± SEM (n = 3; *P < 0.0001 versus Con, one-
way ANOVA). C) Parental cells in 10% DCC-FBS were treated with ± 2 µM AZD5363 or 1 µM selumetinib. Media and drugs were replenished
every three days. When control monolayers reached 60% to 80% confluency (after 15 (MCF-7), 36 (ZR75-1 and MDA-361) or 38 (HCC-1428) days,
respectively), cells were fixed and stained with crystal violet. Representative images and quantification of integrated intensity (% control) are
shown (*P <0.05 versus control, t-test). ANOVA, analysis of variance; DCC-FBS, dextran/charcoal-treated fetal bovine serum; LTED, long-term
estrogen deprivation; SEM, standard error of the mean.
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with this crosstalk, inhibition of AKT with AZD5363
resulted in upregulation of ER mRNA in LTED lines
(Figure 2A). We also saw upregulation of ER protein
and its transcriptional target PR in T47D, MCF-7 and
MDA-361 cells following treatment with the pan-PI3K
inhibitor BKM120 [17] [see Additional file 2, Figure S3),
suggesting that this feedback also occurs with other
inhibitors of the PI3K/AKT pathway. Treatment with
the ER downregulator fulvestrant significantly enhanced
the growth-inhibitory effects of AZD5363 in MCF-7/
LTED cells, and addition of AZD5363 significantly
enhanced the ability of fulvestrant to block estrogen-
induced cell proliferation (Figure 2B).
We next assessed the effects of the AKT inhibitor ± ful-
vestrant on tumor growth in vivo. ER+/PIK3CA mutant
MCF-7 xenografts were established in ovariectomized
athymic female mice supplemented with a 14-day-release
E2 pellet. The E2 pellets expired after 14 days. Four weeks
after tumor cell inoculation, mice with tumors measuring
≥150 mm3 were randomized to treatment with vehicle,
AZD5363, fulvestrant or the combination. AZD5363 and
fulvestrant significantly inhibited tumor growth compared
to vehicle-treated controls (Figure 2C). Treatment with
both AZD5363 and fulvestrant suppressed xenograft
growth >90%; this effect was statistically better than either
drug alone (Figure 2C). AZD5363-treated tumors exhib-
ited lower levels of P-PRAS40 and P-S6 but higher levels
of P-AKT compared to control tumors (Figure 2D). Treat-
ment with fulvestrant alone or with both drugs downregu-
lated ER and IGF-IR protein levels. Tumors treated with
fulvestrant for six weeks exhibited higher levels of T308
P-AKT (Figure 2D). Finally, addition of AZD5363
enhanced fulvestrant-induced inhibition of tumor cell pro-
liferation as measured by Ki67 IHC [see Additional file 2,
Figure S4]. These data suggest that simultaneous inhibi-
tion of AKT and ER is more effective than inhibition of
each molecular target alone against MCF-7 xenografts in
vivo. They also imply that AKT and ER inhibitors induce
an adaptive response that limits their efficacy as single
agents; that is, cells may compensate by signaling with the
alternative (spared) pathway when only one pathway is
inhibited.
Inhibition of AKT was also effective against other
models of endocrine resistance. HBCx-3 ER+ luminal B
breast cancer xenografts were established in nude mice
after resection from a post-menopausal woman with no
previous treatment [21]. These xenografts were negative
for PTEN and HER2 protein by IHC [see Additional
file 2, Figure S5A]. Although these xenografts were
resistant to tamoxifen and fulvestrant, treatment with
AZD5363 suppressed tumor growth [see Additional file 2,
Figure S5B-C]. Further, AZD5363 treatment increased ER
protein levels in the HBCx-3 xenografts [see Additional
file 2, Figure S5D], suggesting that active AKT represses
ER expression both in vitro (Figure 2A; Additional file 2,
Figure S3) and in vivo.
Inhibition of AKT results in upregulation of RTKs in vitro
and in vivo
We and others have previously reported that inhibition
of PI3K/AKT/mTOR induces compensatory expression
and activation of several RTKs [22-24]. In order to iden-
tify inhibitors that can be rationally combined with the
AKT antagonist in hormone-independent breast cancer,
we examined the effects of AZD5363 on a set of thera-
peutically targetable RTKs. Treatment with AZD5363
upregulated mRNA levels of several RTKs, with InsR,
HER3 and IGF-IR being the top hits across all four
LTED lines (Figure 3A). FGFR 2-4 mRNAs were also
induced upon treatment with AZD5363. Inhibition of
AKT resulted in upregulation of total and phosphory-
lated HER3 in three of the four LTED lines, as well as
Y416 P-Src protein levels (Figure 3B). Treatment with
2 µM AZD5363 upregulated InsR protein 1.4-fold in
MCF-7/LTED cells and 5.7-fold in MDA-361/LTED cells
(see densitometric analysis in Figure 3B). Treatment with
the Src kinase inhibitor dasatinib [25] decreased
AZD5363-induced upregulation of phosphorylated HER3
in MCF-7/LTED cells, as well as significantly enhanced
the growth inhibitory effects of AZD5363 [see Additional
file 2, Figure S6A-B]. However, treatment with the Src
inhibitor AZD0530 [26] was ineffective. Pre-treatment
with the IGF-IR/InsR dual TKI AEW541 [27] or
BKM120 abrogated the AZD5363-induced increase in
P-Src [see Additional file 2, Figure S6C], suggesting the
increase in active Src was due to activation of IGF-IR/
InsR and PI3K.
We next assessed the effects of AZD5363 on a wider
panel of RTKs. Following inhibition of AKT in MCF-7/
LTED, ZR75-1/LTED and MDA-361/LTED cells, phos-
pho-RTK array analysis revealed increased phosphorylation
of multiple RTKs, including InsR, IGF-IR, HER3, EGFR,
HER2, HER4, Dtk, VEGFR1 and FGFR2-4 (Figure 3C;
Additional file 2, Figure S7). To validate these findings
in vivo, we treated ovariectomized mice bearing MCF-7
xenografts with AZD5363 for one or three days. Inhibition
of AKT upregulated the tumor levels of P-InsR/IGF-IR,
InsR, P-HER3, HER3, P-HER2, HER2, the FGFR substrate
P-FRS2 and FGFR2 proteins (Figure 3D). Further, treat-
ment with AZD5363 for one to three days also increased
tumor levels of InsR, IGF-IR and FGFR 1-4 mRNAs
(Figure 3E).
Inhibition of IGF-IR/InsR or PI3K abrogates AZD5363-
induced AKT membrane localization and phosphorylation
We speculated that upregulation of activated InsR/IGF-IR
was maintaining PI3K activity and PIP3 formation to
counteract the inhibition of AKT and, thus, limit the
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action of AZD5363. To test this possibility, we transfected
MCF-7/LTED cells with a fusion protein comprised of the
AKT PH domain fused to the amino-terminus of GFP
[24,28]. PIP3 binding to the PH domain should result in
translocation of the fusion protein to the plasma mem-
brane. AKT PH-GFP was mainly cytoplasmic in control
cells, whereas treatment with exogenous IGF-I induced its
translocation to the membrane (Figure 4A). Treatment
with AZD5363 also induced marked translocation of AKT
PH-GFP to the membrane, suggestive of increased PIP3
production and, as a result, AKT phosphorylation at the
T308 PDK-1 site. Pre-treatment with the IGF-IR/InsR TKI
AEW541 or BKM120 prevented AZD5363-induced mem-
brane localization of AKT PH-GFP (Figure 4A), as well
as abrogated the AZD5363-induced increase in AKT
phosphorylation at T308 and S473 in three LTED lines
(Figure 4B). Combined treatment with BKM120 and
AZD5363 resulted in greater inhibition of P-PRAS40 and
Figure 2 Combined inhibition of AKT and ER suppresses hormone-independent tumor growth. A) LTED cells were treated with 10% DCC-FBS ±
2 µM AZD5363 for 24 hours. RNA was extracted, reverse transcribed to cDNA and analyzed by real-time PCR. Threshold cycle values were normalized
for actin. Data are presented as fold versus control; each bar, mean ± SEM (n = 2; *P < 0.0001 versus Con, two-way ANOVA). B) LTED cells were treated
with 10% DCC-FBS ± 2 µM AZD5363, 1 µM fulvestrant or 1 nM E2. Media and drugs were replenished every three days. Cells were counted after five
days. Data are presented as percent of control; each bar, mean ± SEM (n = 3; *P < 0.0001 versus Con or E2; #P < 0.01 versus AZD or fulvestrant; ^P <
0.01 versus E2 + fulvestrant, one-way ANOVA). C) MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release 17b-estradiol
pellets. Mice bearing tumors ≥150 mm3 were randomized to vehicle, AZD5363 (150 mg/kg/day bid), fulvestrant (5 mg/wk), or AZD5363 + fulvestrant for
six weeks. Data are presented as mean tumor volume ± SEM (*P <0.01 versus vehicle; #P < 0.001 versus AZD or fulvestrant, t-test). D) Xenografts from C)
were homogenized one hour after the last dose and tumor lysates were analyzed by immunoblot using the indicated antibodies. ANOVA, analysis of
variance; DCC-FBS, dextran/charcoal-treated fetal bovine serum; LTED, long-term estrogen deprivation; SEM, standard error of the mean.
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P-GSK-3 compared to each inhibitor alone (Figure 4B).
Together, these data suggest that following inhibition of
AKT in LTED cells, the phosphorylation of AKT is at least
in part due to compensatory upregulation of IGF-IR/InsR
signaling and PIP3 formation.
Inhibition of AKT results in FoxO-dependent upregulation
of IGF-IR/InsR ligands
We next investigated mechanisms of IGF-IR/InsR phos-
phorylation upon inhibition of AKT. Treatment with
AZD5363 (24 hours) upregulated mRNA levels of IGF-I
Figure 3 Inhibition of AKT results in feedback upregulation of RTKs. A) LTED cells were treated with 10% DCC-FBS ± 2 µM AZD5363 for
24 hours. RNA was extracted, reverse transcribed to cDNA and analyzed by real-time PCR. Threshold cycle values were normalized for actin.
Average fold changes over control (Con) were calculated and used to generate a heatmap. B) LTED cells were treated for 24 hours in 10%
DCC-FBS ± 15 µM AZD5363. Protein lysates were analyzed by immunoblot. Densitometric analysis was performed and the ratio of InsR:actin is
shown below the InsR blots. C) LTED cells in 10% DCC-FBS were treated ± 2 µM AZD5363 for 0 to 24 hours. Cell lysates (0.5 mg) were prepared
and analyzed by phospho-RTK arrays. D) Mice bearing MCF-7 xenografts ≥150 mm3 were treated with vehicle or AZD5363 (150 mg/kg bid p.o.)
for one or three days. Xenografts were harvested four hours after the last dose; tumor lysates were prepared and analyzed by immunoblot.
Densitometric analysis was performed and a graphical representation of the average RTK:actin levels is shown below the blot. E) Xenografts from
D) were homogenized and RNA was extracted and analyzed by real-time PCR as in A. Data are presented as fold versus control; each bar,
mean ± SEM (n = 3; *P <0.05 versus Con, t-test). DCC-FBS, dextran/charcoal-treated fetal bovine serum; LTED, long-term estrogen deprivation;
RTK, receptor tyrosine kinase; SEM, standard error of the mean.
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and IGF-II in three of the four LTED cell lines (Figure 5A),
as well as in MCF-7 and ZR75-1 xenografts (Figure 5B). E2
induction of IGF-II mRNA in T47D cells served as a posi-
tive control for IGF-II expression (Figure 5A). Treatment
with AZD5363 also increased IGF-I and IGF-II protein
levels in the cell culture supernatants of three of the four
LTED lines [see Additional file 2, Figure S8]. IGF-I and
IGF-II bind IGF-IR/InsR heterodimers and IGF-IR homo-
dimers [29]. Of note, short-term treatment of MCF-7 and
ZR75-1 xenografts with AZD5363 downregulated mRNA
levels of IGF binding protein 3 (IGFBP-3) (Figure 5B),
which blocks binding of IGFs to their cognate receptors
[30].
Estrogen is known to modulate IGF-I signaling in breast
cancer, and ER induces IGF-IR and IGF-II expression [31].
The IGF-IR and InsR gene promoters also contain binding
sites for the FoxO transcription factors, including FoxO3a,
which is inhibited when phosphorylated by AKT [32].
FoxO proteins can bind directly to insulin-responsive
sequences (IRSs), such as those found in the IGFBP-1 pro-
moter, or IRS-like DNA-sequences [33]. Blockade of AKT
inhibits FoxO3a phosphorylation, resulting in transloca-
tion of FoxO3a to the nucleus, where it regulates gene
transcription. Further, FoxO3a has been shown to interact
functionally with ER [34-38], prompting us to speculate
that IGF-IR, IGF-I, and IGF-II are regulated by both ER
Figure 4 Inhibition of IGF-IR/InsR or PI3K abrogates AZD5363-induced AKT membrane localization and phosphorylation. A) MCF-7/LTED
cells were transfected with an AKT PH-GFP plasmid. On day four, cells were treated with 100 ng/ml IGF-I in serum-free medium for 15 minutes, or
pre-incubated with 10% DCC-FBS ± 1 µM AEW541 or 1 µM BKM120 for 30 minutes followed by treatment with 2 µM AZD5363 for four hours. Cells
were viewed in a LSM 510Meta confocal microscope at 40x magnification. B) LTED lines were treated with 10% DCC-FBS ± 1 µM AEW541 or
BKM120 for 1 hour, followed by the addition of 2 µM AZD5363 for 24 hours. Protein lysates were analyzed by immunoblot using the indicated
antibodies. DCC-FBS, dextran/charcoal-treated fetal bovine serum; IGF-I, insulin-like growth factor-I; LTED, long-term estrogen deprivation.
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and FoxO. Since AZD5363 induces FoxO3a nuclear trans-
location in ER+/PIK3CA mutant breast cancer cells [15]
and ER mRNA in LTED cells (Figure 2A), we examined
whether knockdown of ER and/or FoxO3a affects
AZD5363-induced transcription of IGF-IR, InsR, and IGF
ligands. siRNA-mediated knockdown was confirmed by
RT qPCR (Figure 5C). Downregulation of FoxO3a or ER,
either alone or in combination, abrogated AZD5363-
Figure 5 AZD5363-induced upregulation of IGF-IR, IGF-I and IGF-II is dependent on ER and FoxO3. A) LTED cells were treated with 10% DCC-
FBS ± 2 µM AZD5363 for 24 hours. T47D cells were serum starved for 24 hours and then treated with 10% DCC-FBS ± 2 µM AZD5363 for 24 hours.
RNA was extracted, reverse transcribed to cDNA and analyzed by real-time PCR. Threshold cycle values were normalized for actin. qPCR reactions with
no input RNA were used as negative controls. Data are presented as fold versus control; each bar, mean ± SEM (n = 4; *P <0.05 versus Con, t-test).
B) Mice bearing MCF-7 or ZR75-1 xenografts ≥150 mm3 were treated with vehicle or AZD5363 (150 mg/kg bid) for one day. Xenografts were
harvested four hours after the last dose and homogenized. RNA was extracted, reverse transcribed to cDNA and analyzed by real-time PCR. Threshold
cycle values were normalized for actin (MCF-7) or 36B4 (ZR75-1). Data are presented as fold versus control; each bar, mean ± SEM (n = 3; *P < 0.05
versus Con, t-test). C, D) MCF-7/LTED cells were transfected with siRNA targeting FoxO3, ER, both (siboth) or a non-silencing control (siCon). Two days
later the cells were treated with 10% DCC-FBS ± 2 µM AZD5363 for 24 hours. RNA was extracted and analyzed by real-time PCR as in A. Data are
presented as fold versus control; each bar, mean ± SEM (n = 3). C) *P <0.01 versus siCon, t-test. D) *P <0.05 versus siCon; #P <0.05 versus AZD, t-test.
DCC-FBS, dextran/charcoal-treated fetal bovine serum; ER, estrogen receptor; FoxO, forkhead box class O; LTED, long-term estrogen deprivation.
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mediated induction of IGF-IR, IGF-I, IGF-II and ER
mRNA (Figure 5C-D). Knockdown of FoxO3a, but not ER,
inhibited the induction of InsR mRNA following treatment
with AZD5363 (Figure 5D). This result was expected,
since InsR is not ER-regulated. These results suggest that
the AZD5363-induced upregulation of IGF-IR, IGF-I, and
IGF-II is dependent on ER and FoxO3a, whereas upregula-
tion of InsR is dependent on FoxO3a.
We then postulated that the phosphorylation of IGF-
IR/InsR upon inhibition of AKT would be inhibited by
blocking ligand binding to receptors with IGFBP-3.
Treatment of MCF-7/LTED cells with IGFBP-3 inhibited
IGF-I and IGF-II-induced phosphorylation of IGF-IR/
InsR, as well as AKT (Figure 6A). IGFBP-3 also blocked
AZD5363-induced phosphorylation of the IGF-IR and
InsR, but not HER3 (Figure 6B). Further, IGFBP-3 com-
pletely blocked the AZD5363-induced increase in T308
P-AKT and partially that of S473 P-AKT (Figure 6C), sug-
gesting IGF blockade inhibited PIP3 production and AKT
tethering to the plasma membrane. This result suggests
that the increase in IGF-IR/InsR ligands was causal to the
phosphorylation of IGF-IR/InsR and AKT upon inhibition
of AKT with AZD5363.
Pharmacological inhibition of IGF-IR/InsR enhances the
anti-tumor effect of AZD5363 in vivo
Since LTED cells compensate for AKT inhibition by
upregulating IGF-IR/InsR activity (Figure 3), we exam-
ined whether inhibition of this pathway sensitizes to the
AKT inhibitor. siRNA-mediated knockdown of IGF-IR
or InsR, but not HER3, significantly enhanced the
growth inhibitory effects of AZD5363 in MCF-7 cells
(Figure 7A,B). We next investigated the effects of the
reversible, ATP-competitive dual IGF-IR/InsR TKI
AZD9362. AZD9362 inhibits autophosphorylation of
IGF-IR in fibroblasts from an IGF-IR knockout mouse
stably transfected with human IGF-IR (IC50 of 48 nM),
as well as autophosphorylation of InsR in CHO cells
transfected with human InsR (IC50 of 186 nM; AstraZe-
neca, unpublished data). Treatment with AZD9362 also sig-
nificantly sensitized cells to the AKT inhibitor (Figure 7C),
suggesting that LTED cells compensate for AKT inhibition
by upregulating IGF-IR/InsR kinase activity. Since inhibi-
tion of AKT with AZD5363 upregulated both IGF-IR/InsR
and FGFR activity in vivo (Figure 3D-E), we next assessed
the combination of AZD5363 with AZD9362 or with the
FGFR TKI AZD4547 against MCF-7 xenografts. AZD4547
potently inhibits the FGFR1, 2 and 3 tyrosine kinases (IC50
of 0.2, 2.5 and 1.8 nM, respectively), but displays weaker
activity against FGFR4 (IC50 of 165 nM) [19]. Treatment
with AZD5363 or AZD9362 but not the FGFR antagonist
inhibited tumor growth compared to vehicle (P < 0.05;
Figure 7D). This was consistent with the report that 30 µM
of AZD4547 did not affect MCF-7 proliferation in vitro
[19]. Addition of AZD4547 to AZD5363 modestly
increased its anti-tumor effect, albeit not significantly.
However, combined treatment with AZD5363 and the
InsR/IGF-IR inhibitor AZD9362 was significantly superior
to AZD5363 alone (P = 0.004), inducing a complete tumor
regression in one mouse (Figure 7D). Overall, the drug
combinations were well-tolerated with <10% weight loss
[see Additional file 2, Figure S9]. These results suggest that
combined inhibition of AKT and IGF-IR/InsR is more
effective against MCF-7 xenografts established in ovariecto-
mized mice.
Discussion
PI3K/AKT/mTOR pathway activation has been implicated
in endocrine resistance in breast cancer [9,10,12-14]. High
AKT expression in breast tumors has also been associated
with a poor response to antiestrogen therapy [39,40]. In
support of this notion, we show herein that the catalytic
AKT inhibitor AZD5363 inhibited the growth of ER+
human breast cancer cells with acquired resistance to
estrogen deprivation and prevented the emergence of hor-
mone-independent cells. Inhibition of AKT suppressed
growth of MCF-7 xenografts in ovariectomized mice and
in a patient-derived breast cancer resistant to tamoxifen
and fulvestrant. Combined inhibition of ER and AKT was
more effective than each intervention alone. AKT inhibi-
tion resulted in feedback upregulation and activation of
RTKs in vitro and in vivo, including IGF-IR, InsR, HER3
and FGFRs. Inhibition of IGF-IR/InsR or PI3K abrogated
AKT PH-GFP membrane localization and AKT phosphor-
ylation following treatment with AZD5363. Inhibition of
AKT resulted in upregulation of ER- and FoxO-dependent
IGF-IR, IGF-I, and IGF-II. Treatment with IGFBP-3
blocked the AZD5363-induced phosphorylation of IGF-
IR/InsR and AKT, suggesting that the induced ligands
activated IGF-IR/InsR. Finally, inhibition of IGF-IR/InsR
enhanced the antitumor effect of the AKT inhibitor both
in vitro and in vivo.
Inhibition of AKT with AZD5363 resulted in upregu-
lation and activation of several RTKs. Others have seen
upregulation of RTKs upon inhibition of the PI3K/AKT/
mTOR pathway, including HER3 [22-24]. We show that
this feedback reactivation also occurs in antiestrogen-
resistant breast cancer cells and xenografts using a cata-
lytic inhibitor of AKT. AZD5363 treatment resulted in
prominent upregulation of IGF-IR/InsR expression and
activity both in vitro and in vivo (Figure 3). In turn,
InsR/IGF-IR stimulated membrane localization and
phosphorylation of AKT in T308 likely as a result of
increased production of PIP3. Indeed, inhibition of IGF-
IR/InsR or PI3K abrogated AKT PH-GFP membrane
localization and P-AKT following treatment with
AZD5363 (Figure 4). While the increase in InsR/IGF-IR
levels can be explained by increased FoxO-dependent
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mRNA transcription (Figure 5D; [22,23]), it is less clear
why receptor phosphorylation would increase following
inhibition of AKT. However, we observed that upon
inhibition of AKT, IGF-I and IGF-II mRNA were
increased whereas IGFBP-3 mRNA levels were reduced
(Figure 5A-B), thus revealing a previously unreported
autocrine loop. Treatment with IGFBP-3 blocked
AZD5363-induced phosphorylation of IGF-IR/InsR and
AKT (Figure 6), suggesting that increased IGF-IR/InsR
ligand production and activation of IGF-IR/InsR acti-
vates PI3K upstream AKT.
Inhibition of the PI3K/AKT pathway using AZD5363 or
BKM120 induced ERa expression (Figure 2A; Additional
file 2, Figure S3). In agreement with our data, Guo and
colleagues reported that constitutively active AKT reduces
ERa expression, whereas AKT inhibition increases ERa
levels [35]. Knockdown of FoxO3a reduced ERa mRNA
and limited the AZD5363-mediated induction of ERa
(Figure 5C), suggesting that its compensatory upregulation
may be dependent on FoxO3a. In support of this, Guo and
colleagues reported that expression of a dominant negative
FoxO3a decreased ERa levels in MCF-7 cells [35]. Further,
FoxO3a has been shown to transactivate ERa[35,38]. In
contrast, others have shown that FoxO3a negatively regu-
lates ER transcriptional activity [34,36,37]. These differing
reports may be due to the use of different cellular systems
and the presence or absence of estrogen. Importantly, we
also identified a novel role for FoxO3a in regulating
AZD5363-induced ER, IGF-I and IGF-II transcription.
Further, AZD5363-induced upregulation of IGF-IR, IGF-I
and IGF-II mRNA was dually regulated by FoxO3a and
ER (Figure 5D). We propose that inhibition of AKT
induces FoxO3a nuclear translocation [15] and transcrip-
tional activation (Figure 5C), leading to increased ER,
InsR, IGF-IR, IGF-I and IGF-II expression. ER also regu-
lates IGF-IR, IGF-I and IGF-II transcription, ultimately
leading to enhanced phosphorylation of IGF-IR/InsR and
AKT.
Compensation for AKT inhibition through InsR/IGF-
IR signaling has therapeutic implications in cancer.
Although treatment with AZD5363 upregulated HER3
mRNA and protein levels (Figures 3A-B), knockdown of
HER3 did not sensitize to AZD5363 treatment in MCF-7
cells (Figure 7A). Consistent with this result, treatment
with the EGFR/HER2 dual kinase inhibitor lapatinib,
which blocks HER3 phosphorylation in MCF-7 cells,
does not suppress P-AKT in MCF-7 cells [9]. These data
suggest that HER3 does not appreciably activate PI3K in
these cells. In contrast, RNAi-mediated knockdown or
pharmaceutical inhibition of IGF-IR/InsR sensitized
breast cancer cells to the AKT inhibitor (Figures 7A,C).
We have previously identified IGF-IR/InsR signaling as a
mechanism of escape from hormone dependence in ER+
breast cancer [41]. In keeping with this, inhibition of
Figure 6 IGFBP-3 blocks AZD5363-induced phosphorylation of IGF-IR/InsR and AKT. A) MCF-7/LTED cells were treated overnight with serum-
free medium ± 1.5 µg/ml IGFBP-3, followed by treatment for 15 minutes ± 100 ng/ml IGF-I or IGF-II. Protein lysates were analyzed by immunoblot
using the indicated antibodies. B) MCF-7/LTED cells in 10% DCC-FBS were treated ± 1.5 µg/ml recombinant IGFBP-3 for 1 hour followed by 2 µM
AZD5363 for 24 hours. Cell lysates (0.5 mg) were prepared and analyzed by phospho-RTK arrays. C) MCF-7/LTED cells in 10% DCC-FBS were treated ±
1.5 µg/ml IGFBP-3 for 1 hour followed by 2 µM AZD5363 for 24 hours. Protein lysates were prepared and analyzed by immunoblot using the indicated
antibodies. DCC-FBS, dextran/charcoal-treated fetal bovine serum; IGF, insulin-like growth factor; LTED, long-term estrogen deprivation.
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IGF-IR/InsR with AZD9362 suppressed MCF-7 xenograft
growth in ovariectomized mice devoid of estrogen sup-
plementation (Figure 7D). Importantly, treatment with
AZD9362 also enhanced the anti-tumor effects of the
AKT inhibitor against MCF-7 xenografts (Figure 7D),
suggesting that combined inhibition of IGF-IR/InsR and
AKT should be more effective than either agent alone in
treating ER+ breast cancers that adapt to estrogen depri-
vation. We also showed that long-term treatment with
the pan-PI3K inhibitor BKM120 increased IRS-1 levels in
T47D cells [see Additional file 2, Figure S3], providing an
additional rationale for combining PI3K/AKT and IGF-
IR/InsR antagonists. Addition of the FGFR inhibitor
AZD4547 also increased the anti-tumor effects of
AZD5363 in vivo, albeit modestly (Figure 7D). FGFR1
amplification has been shown to drive endocrine therapy
resistance, and patients with ER+ positive tumors that
overexpress FGFR1 exhibit a shorter relapse-free survival
after adjuvant tamoxifen [42]. Thus, combined inhibition
of AKT with FGFR in the setting of antiestrogen resis-
tance warrants further investigation.
Conclusions
Upregulation of IGF-IR/InsR and their ligands compen-
sates for AKT inhibition in breast cancer cells with
acquired resistance to estrogen deprivation, implying
that AKT inhibitors may have limited clinical activity in
endocrine-resistant breast cancers when used as single
Figure 7 Inhibition of IGF-IR/InsR enhances the anti-tumor effect of the AKT inhibitor AZD5363. A) MCF-7 cells were transfected with
siRNA specific for a non-silencing control (siCon), InsR, IGF-IR or HER3 and re-seeded the next day for assessment of growth in monolayer (A) or
immunoblot analyses (B). In A, cells were treated with 10% DCC-FBS ± 2 µM AZD5363 and counted after five days. Data are presented as % of
control; mean ± SEM (n = 3; *P < 0.0001 versus each Con, #P < 0.01 versus siCon + AZD; two-way ANOVA). In B, cells were grown in 10% DCC-
FBS and harvested three days later; lysates were analyzed by immunoblot using the indicated antibodies. C) MCF-7/LTED cells in 10% DCC-FBS
were treated ± 2 µM AZD5363 or 1 µM AZD9362. Media and drugs were replenished every three days. Cells were counted after five days. Data
are presented as % of control; mean ± SEM (n = 2; *P < 0.0001 versus Con, #P < 0.05 versus 5363 or 9362; one-way ANOVA). D) Mice bearing
MCF-7 xenografts ≥150 mm3 were randomized to the indicated treatments. Data are presented as mean tumor volume ± SEM (*P < 0.05 versus
vehicle; #P = 0.0041 versus AZD5363, t-test). ANOVA, analysis of variance; DCC-FBS, dextran/charcoal-treated fetal bovine serum; IGF, insulin-like
growth factor; LTED, long-term estrogen deprivation; SEM, standard error of the mean.
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agents. Inhibition of the IGF-IR/InsR signaling pathway
enhanced the action of AZD5363 against estrogen-
deprived breast cancers, suggesting that combined treat-
ment with an AKT inhibitor and a dual IGF-IR/InsR
TKI merits evaluation as a potential treatment for endo-
crine-resistant breast cancer.
Additional material
Additional file 1: Supplementary materials and methods for
Supplementary figures. A pdf file presenting the Supplementary
materials and methods.
Additional file 2: Supplementary figures S1-S9. Figure S1 showing
inhibition of AKT with AZD5363 reduces phosphorylation of AKT/TORC1
substrates in ER+ breast cancer cells. Figure S2 showing inhibition of AKT
with AZD5363 prevents the emergence of hormone-independent ER+
breast cancer cells. Figure S3 showing inhibition of PI3K with BKM120
upregulates ER expression and activity. Figure S4 showing treatment with
AZD5363 and fulvestrant synergistically inhibits proliferation in vivo.
Figure S5 showing AKT inhibition suppresses the growth of HBCx-3 ER+
luminal B breast cancer xenografts. Figure S6 showing the Src inhibitor
dasatinib suppresses AZD5363-induced upregulation of HER3
phosphorylation and enhances its growth inhibitory effects. Figure S7
showing inhibition of AKT is followed by phosphorylation of multiple
RTKs. Figure S8 showing inhibition of AKT with AZD5363 upregulates
IGF-I and IGF-II protein levels. Figure S9 showing mice exhibit minimal
weight loss when treated with pharmacological inhibitors.
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